CN103751424A - Preparation method of cold tablet containing Artemisia carvifolia and holly root, and application of cold tablet in teratoma cell F9 cell proliferation inhibition medicines. - Google Patents
Preparation method of cold tablet containing Artemisia carvifolia and holly root, and application of cold tablet in teratoma cell F9 cell proliferation inhibition medicines. Download PDFInfo
- Publication number
- CN103751424A CN103751424A CN201310652780.3A CN201310652780A CN103751424A CN 103751424 A CN103751424 A CN 103751424A CN 201310652780 A CN201310652780 A CN 201310652780A CN 103751424 A CN103751424 A CN 103751424A
- Authority
- CN
- China
- Prior art keywords
- preparation
- cold tablet
- extraction
- common cold
- armeniaca mume
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and concretely relates to a preparation method of a cold tablet containing Artemisia carvifolia and holly root, and an application of the cold tablet. The preparation method of the cold tablet containing Artemisia carvifolia and holly root is characterized in that the cold tablet is prepared by using 200g of Artemisia carvifolia, 267g of Fructus Citri Sarcodactylis, 134g of Herba Moslae, 200g of Dicliptera chinensis, 134g of licorice root, 134g of Centella asiatica and 267g of holly root as raw medicines through supercritical extraction and microwave extraction, so the glycyrrhizic acid content is greatly improved. The invention also provides an application of the cold tablet containing Artemisia carvifolia and holly root in the preparation of teratoma cell F9 cell proliferation inhibition medicines.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to a kind of preparation method of Armeniaca mume Sieb. common cold tablet and the application in inhibition mice teratocarcinoma cell F9 cell proliferation medicine thereof.
Background technology
Armeniaca mume Sieb. cold granules standard No. WS-11318 (ZD-1318)-2002, is recorded in national standard for traditional Chinese medicines compilation internal medicine taste fascicle.By Herba Artemisiae Annuae 200g, Folium vilicis Negundo 267g, Herba Moslae 134g, Herba Diclipterae Chinensis 200g, Radix Glycyrrhizae 134g, Herba Centellae 134g, Flos Ilicis Asprellae 267g, as crude drug, made, there is refrigerant antipyretic effect.For anemopyretic cold, headache, cough, nasal obstruction.
In prior art, not yet have Armeniaca mume Sieb. cold granules at the report that adopts supercritical and microwave technology aspect extraction preparation, and volatile oil extracts, the method that decocting boils, technique is coarse, backward, and impurity is many, cause patient's consumption excessive, be inconvenient to take, had a strong impact on this product and applied clinically.
Summary of the invention
In order to solve above-mentioned technical problem, the invention provides a kind of preparation method of Armeniaca mume Sieb. common cold tablet.
Another object of the present invention is to provide a kind of Armeniaca mume Sieb. common cold tablet to suppress the application in mice teratocarcinoma cell F9 cell proliferation medicine in preparation.
The object of the invention is to realize by following scheme:
A kind of preparation method of Armeniaca mume Sieb. common cold tablet, by Herba Artemisiae Annuae 200g, Folium vilicis Negundo 267g, Herba Moslae 134g, Herba Diclipterae Chinensis 200g, Radix Glycyrrhizae 134g, Herba Centellae 134g, Flos Ilicis Asprellae 267g, as crude drug, made, described preparation method is comprised of the following step: get Herba Artemisiae Annuae, Herba Moslae, join CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4-6%, extracting pressure 15-30MPa, temperature 30-50 ℃, CO
2flow l-3ml/g crude drug min, extraction time 180-220min, obtains supercritical extract, standby; Get all the other Chinese medicines, pulverize, add 50% ethanol of 5L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 600-800W, extracts 2 times, each 5-10 minute, combining extraction liquid, concentrated, be added on Dl01 macroporous adsorptive resins, 50% ethanol elution, collects 5 times of amount column volume eluents, decompression recycling ethanol, concentrate and be dried, obtain microwave extraction thing, standby; Above-mentioned supercritical extract and microwave extraction thing are mixed, add starch, 70% ethanol granule processed, dry, tabletting, makes 150, every heavy 0.3g.
In the preparation method of above-mentioned Armeniaca mume Sieb. common cold tablet, described CO
2in supercritical extraction, to account for the percent by volume of total extractant be 5% to entrainer.
In the preparation method of above-mentioned Armeniaca mume Sieb. common cold tablet, described CO
2in supercritical extraction, extracting pressure is 25MPa.
In the preparation method of above-mentioned Armeniaca mume Sieb. common cold tablet, described CO
2in supercritical extraction, extraction temperature is 60 ℃.
In the preparation method of above-mentioned Armeniaca mume Sieb. common cold tablet, described CO
2cO in supercritical extraction
2flow 2ml/g crude drug min.
In the preparation method of above-mentioned Armeniaca mume Sieb. common cold tablet, described CO
2in supercritical extraction, extraction time is 200min.
In the preparation method of above-mentioned Armeniaca mume Sieb. common cold tablet, described microwave extracting power is 700W.
In the preparation method of above-mentioned Armeniaca mume Sieb. common cold tablet, the each extraction time of described microwave extracting is 8 minutes.
Above-mentioned Armeniaca mume Sieb. common cold tablet suppresses the application in mice teratocarcinoma cell F9 cell proliferation medicine in preparation.
In prior art, each 1 bag of Armeniaca mume Sieb. cold granules, every bag of 15g, 2-3 time on the one.Armeniaca mume Sieb. cold granules dosage is large, and granule preparation need to add a large amount of sugar, and diabetics is not suitable for, and the words taste of not sugaring is not good, and patient is not easy under clothes, and compliance is poor.The every heavy 0.3g of Armeniaca mume Sieb. common cold tablet that adopts the inventive method to be prepared into only needs 2 at every turn, within 1st, takes 2-3 time.Under the condition with more active component, greatly reduced dose.This conclusion can be by following evidence.And be prepared into tablet, patient swallows with water, dosage is little and without bitterness, patient is easy to accept.
The comparison of glycyrrhizic acid content in Armeniaca mume Sieb. common cold tablet prepared by test one, distinct methods
L, instrument and reagent Armeniaca mume Sieb. common cold tablet of the present invention: press embodiment 1 method preparation, use 1510g crude drug, make 150 through extracting, every heavy 0.3g.Former Armeniaca mume Sieb. cold granules, prepares according to WS-11318 (ZD-1318)-2002 standard method.Agilent1200 high performance liquid chromatograph; METTLER AE240 electronic analytical balance; Glycyrrhizic acid reference substance (Nat'l Pharmaceutical & Biological Products Control Institute).
2, method
According to high performance liquid chromatography (appendix VI D of Chinese Pharmacopoeia version in 2010), measure.
Chromatographic condition and system suitability octadecylsilane chemically bonded silica are filler; Methanol-0.2mol/L Spirit of Mindererus .-glacial acetic acid (67: 33: 1) is mobile phase; Detection wavelength is 250nm.Number of theoretical plate calculates and should be not less than 3000 by glycyrrhizic acid peak.
It is appropriate that the preparation precision of reference substance solution takes monoammonium glycyrrhizinate reference substance, adds 90% methanol and make the solution of every 1ml containing 0.4mg, obtains.
Armeniaca mume Sieb. common cold tablet of the present invention is got in the preparation of need testing solution, and porphyrize, gets 0.08g, accurately weighed, to put in tool plug conical flask, precision adds 90% methanol 10ml, close plug, weighed weight, supersound process 30 minutes, let cool, more weighed weight, with 90% methanol, supply the weight of less loss, centrifugal, (0.45 μ m) filters microporous filter membrane for supernatant, gets subsequent filtrate, obtains.
The Armeniaca mume Sieb. cold granules of this contrast is got in the preparation of reference product need testing solution, and porphyrize, mixes, get 2g, accurately weighed, put in tool plug conical flask, precision adds 90% methanol 10ml, close plug, weighed weight, supersound process 30 minutes, lets cool, more weighed weight, with 90% methanol, supply the weight of less loss, centrifugal, (0.45 μ m) filters microporous filter membrane for supernatant, get subsequent filtrate, obtain.
Algoscopy is accurate reference substance solution and the each 20 μ l of need testing solution of drawing respectively, and injection liquid chromatography, measures, and obtains.3, result
Result shows, in Armeniaca mume Sieb. common cold tablet of the present invention, the content of glycyrrhizic acid is 35-70mg/ sheet; And the content of glycyrrhizic acid is 14.5mg/ bag in former Armeniaca mume Sieb. cold granules, each serving the glycyrrhizic acid content of 2 of consumptions, be 5-10 times of former granule content, in the situation that dose reduces, glycyrrhizic acid content improves a lot.
Above-mentioned research shows, the Armeniaca mume Sieb. common cold tablet that adopts preparation method of the present invention to prepare, Armeniaca mume Sieb. cold granules prepared by the method that active constituent content is recorded higher than WS-11318 (ZD-1318)-2002 standard far away.
The specific embodiment
Below in conjunction with specific embodiment, the present invention is further described, so that those skilled in the art more understands the present invention, but this should be interpreted as to the scope of the above-mentioned theme of the present invention only limits to following example, all technology realizing based on foregoing of the present invention all belong to scope of the present invention.
Embodiment 1
Get Herba Artemisiae Annuae 200g, Folium vilicis Negundo 267g, Herba Moslae 134g, Herba Diclipterae Chinensis 200g, Radix Glycyrrhizae 134g, Herba Centellae 134g, Flos Ilicis Asprellae 267g, Herba Artemisiae Annuae, Herba Moslae are joined to CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 5%, extracting pressure 25MPa, 40 ℃ of temperature, CO
2flow 2ml/g crude drug min, extraction time 200min, obtains supercritical extract, standby; Get all the other Chinese medicines, pulverize, add 50% ethanol of 5L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 700W, extracts 2 times, each 8 minutes, combining extraction liquid, concentrated, be added on Dl01 macroporous adsorptive resins, 50% ethanol elution, collects 5 times of amount column volume eluents, decompression recycling ethanol, concentrate and be dried, obtain microwave extraction thing, standby; Above-mentioned supercritical extract and microwave extraction thing are mixed, add starch, 70% ethanol granule processed, dry, tabletting, makes 150, every heavy 0.3g.
After testing, in finished product, the content of glycyrrhizic acid is 69.8mg/ sheet.
Embodiment 2
Get Herba Artemisiae Annuae 200g, Folium vilicis Negundo 267g, Herba Moslae 134g, Herba Diclipterae Chinensis 200g, Radix Glycyrrhizae 134g, Herba Centellae 134g, Flos Ilicis Asprellae 267g, Herba Artemisiae Annuae, Herba Moslae are joined to CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4%, extracting pressure 30MPa, temperature 50 C, CO
2flow 3ml/g crude drug min, extraction time 180min, obtains supercritical extract, standby; Get all the other Chinese medicines, pulverize, add 50% ethanol of 5L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 600W, extracts 2 times, each 5 minutes, combining extraction liquid, concentrated, be added on Dl01 macroporous adsorptive resins, 50% ethanol elution, collects 5 times of amount column volume eluents, decompression recycling ethanol, concentrate and be dried, obtain microwave extraction thing, standby; Above-mentioned supercritical extract and microwave extraction thing are mixed, add starch, 70% ethanol granule processed, dry, tabletting, makes 150, every heavy 0.3g.
After testing, in finished product, the content of glycyrrhizic acid is 56.2mg/ sheet.
Embodiment 3
Get Herba Artemisiae Annuae 200g, Folium vilicis Negundo 267g, Herba Moslae 134g, Herba Diclipterae Chinensis 200g, Radix Glycyrrhizae 134g, Herba Centellae 134g, Flos Ilicis Asprellae 267g, Herba Artemisiae Annuae, Herba Moslae are joined to CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 6%, extracting pressure 15MPa, 30 ℃ of temperature, CO
2flow 1ml/g crude drug min, extraction time 220min, obtains supercritical extract, standby; Get all the other Chinese medicines, pulverize, add 50% ethanol of 5L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 800W, extracts 2 times, each 10 minutes, combining extraction liquid, concentrated, be added on Dl01 macroporous adsorptive resins, 50% ethanol elution, collects 5 times of amount column volume eluents, decompression recycling ethanol, concentrate and be dried, obtain microwave extraction thing, standby; Above-mentioned supercritical extract and microwave extraction thing are mixed, add starch, 70% ethanol granule processed, dry, tabletting, makes 150, every heavy 0.3g.
After testing, in finished product, the content of glycyrrhizic acid is 36.9mg/ sheet.
Embodiment 4: Armeniaca mume Sieb. common cold tablet suppresses the experimentation data of mice teratocarcinoma cell F9 cell proliferation
1. experiment material
1.1 experiment cell strains
Mice teratocarcinoma cell F9 cell, Shandong University's laboratory cell bank, DMEM+10%FBS cellar culture.
1.2 Experimental agents
Drugs: Armeniaca mume Sieb. common cold tablet of the present invention: press embodiment 1 method preparation.
Medicinal liquid liquid storage: take 100mg Armeniaca mume Sieb. common cold tablet, be dissolved in 5ml dehydrated alcohol, 0.2 μ m filter filters, 500 μ ldoff pipe subpackages ,-20 ℃ of storages, 0.2 μ m filter filters the use of dehydrated alcohol in order to matched group simultaneously.
1.3 experiment reagent
DMEM (Cat.No.12100-061Lot.No.758137 of GIBCO company); Hyclone (Lot.No.100419 of Tian Hang bio tech ltd, Zhejiang); NaHCO
3(Shanghai hundred million Cat.No.11810-033Lot.No.1088387 of chemical reagent company limited of a specified duration); Trypsin(AMRESCO company); EDTA(AMRESCO company); Penicillin G Sodium Salt (AMRESCO company 1); Streptomycin Sulfate (AMRESCO); Dehydrated alcohol (Zibo Ya Dulan Trade Co., Ltd.); MTT (Biosharp lot number: 0793): PBS(laboratory autogamy);
1.4 experiment equipment
Lycra inverted microscope (German Leica model: DMIL); Visible-ultraviolet light microwell plate detector (U.S. MD company model: SPECTRAMAX190); CO
2incubator (FORMA model: 3111); Super-clean bench (safe and sound company of Su Jing group manufactures model: SW-CJ-ZFD); Pure water instrument (U.S. Sprlng company model: S/N020579); Accurate pipettor (French Gilson Inc model: P2); Electronic balance (German Sai Duolisi company limited model: BT323S); Full-automatic high-pressure autoclave (Japanese SANYO company model: MLS-3020); Table electrothermal air dry oven (Shanghai accurate experimental facilities company model: DHG9123A); Refrigerator (Siemens Company's model: KG18V21TI); Liquid nitrogen container (CBS model: 2001); Low speed centrifuge (Anting Scientific Instrument Factory, Shanghai's model: KA-1000); 0.2 μ m filter (MILLIPORE model: SLGP033RB); 1cm culture dish (NEST company), 96 well culture plates (NEST company); Cell counting count board; Centrifuge tube, pipet, Tips are some.
2. experimental technique
1) F9 cell uses DMEM+10%FBS in 37 ℃, 5%CO
2carry out cellar culture (10cm culture dish), when Growth of Cells is during to logarithmic (log) phase, collecting cell, discards culture fluid, PBS fine laundering 3 times, add 3ml0.25% trypsin-0.04%EDTA, after 37 ℃ of digestion 2min, add wherein 5ml complete medium neutralization reaction, after piping and druming cell, proceeded in centrifuge tube, the centrifugal 5min of 1000rpm, adjusts concentration of cell suspension 3 × 10
4individual/ml.
2) cell kind is entered in 96 well culture plates, every hole adds cell suspension 180 μ l, culture plate put into cell culture incubator (37 ℃, 5%CO
2) cellar culture.
3) according to Growth of Cells situation, generally grow to 50%-70%, add Armeniaca mume Sieb. common cold tablet solution, continue to cultivate 24h.
4) after 24h, add 20 μ l MTT solution (5mg/ml, i.e. 0.5%MTT), continue to cultivate 4h.
5) after 4h, buckle method is removed supernatant, pats dry gently with absorbent paper, and low-speed oscillation 10min on shaking table, as entered 200 μ l dimethyl sulfoxide, is put in every hole, and crystal is fully dissolved.At enzyme-linked immunosorbent assay instrument 490nm place, measure the light absorption value in each hole.
6) background (do not add cell, only add culture fluid) is set simultaneously, control wells (the medicine dissolution medium of cell, same concentrations, culture fluid, MTT, dimethyl sulfoxide), sets 6 multiple holes for every group.
7) result represents the suppression ratio of cell with medicine: cell increment suppression ratio (%)=(control wells OD value-dosing holes OD value), control wells OD value × 100%.Experiment repeats 3 times.
3. statistical disposition
Adopt correlation analysis and Student t check in Microsoft Excel2007 software, data represent with mean ± S.D..
4. experimental result
Statistical result showed after mtt assay experiment, with matched group comparison, when dosage reaches 5mg/ml, to F9 cell inhibitory effect variant (P<0.05), dosage this difference when 10mg/ml has significance (P<0.01), has utmost point significant difference (P<0.001) when dosage reaches 15-20mg/ml.
Table 1 Armeniaca mume Sieb. common cold tablet is on F9 cell inhibitory effect impact research (X ± SD)
| Group | Drug level (mg/ml) | Suppression ratio (%) |
| Matched group | 0 | 0 |
| 1 | 5 | 8.16±7.88 |
| 2 | 10 | 16.23±12.55* |
| 3 | 15 | 33.76±17.28** |
| 4 | 20 | 43.27±19.26** |
Note: with matched group comparison, * P<O.01; * P<0.001.
5. experiment conclusion
Armeniaca mume Sieb. common cold tablet of the present invention can suppress F9 cell proliferation, reduces the Growth of Cells number of F9 cell, and this effect is dose dependent.
Claims (9)
1. the preparation method of an Armeniaca mume Sieb. common cold tablet, by Herba Artemisiae Annuae 200g, Folium vilicis Negundo 267g, Herba Moslae 134g, Herba Diclipterae Chinensis 200g, Radix Glycyrrhizae 134g, Herba Centellae 134g, Flos Ilicis Asprellae 267g, as crude drug, made, it is characterized in that, described preparation method is comprised of the following step: get Herba Artemisiae Annuae, Herba Moslae, join CO
2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4-6%, extracting pressure 15-30MPa, temperature 30-50 ℃, CO
2flow l-3ml/g crude drug min, extraction time 180-220min, obtains supercritical extract, standby; Get all the other Chinese medicines, pulverize, add 50% ethanol of 5L, drop in microwave extracting apparatus and carry out microwave extracting, extraction power 600-800W, extracts 2 times, each 5-10 minute, combining extraction liquid, concentrated, be added on Dl01 macroporous adsorptive resins, 50% ethanol elution, collects 5 times of amount column volume eluents, decompression recycling ethanol, concentrate and be dried, obtain microwave extraction thing, standby; Above-mentioned supercritical extract and microwave extraction thing are mixed, add starch, 70% ethanol granule processed, dry, tabletting, makes 150, every heavy 0.3g.
2. according to the preparation method of the Armeniaca mume Sieb. common cold tablet described in claim l, it is characterized in that described CO
2in supercritical extraction, to account for the percent by volume of total extractant be 5% to entrainer.
3. according to the preparation method of the Armeniaca mume Sieb. common cold tablet described in claim l, it is characterized in that described CO
2in supercritical extraction, extracting pressure is 25MPa.
4. according to the preparation method of the Armeniaca mume Sieb. common cold tablet described in claim l, it is characterized in that described CO
2in supercritical extraction, extraction temperature is 60 ℃.
5. according to the preparation method of the Armeniaca mume Sieb. common cold tablet described in claim l, it is characterized in that described CO
2cO in supercritical extraction
2flow 2ml/g crude drug min.
6. according to the preparation method of the Armeniaca mume Sieb. common cold tablet described in claim l, it is characterized in that described CO
2in supercritical extraction, extraction time is 200min.
7. according to the preparation method of the Armeniaca mume Sieb. common cold tablet described in claim l, it is characterized in that, described microwave extracting power is 700W.
8. according to the preparation method of the Armeniaca mume Sieb. common cold tablet described in claim l, it is characterized in that, the each extraction time of described microwave extracting is 8 minutes.
9. the Armeniaca mume Sieb. common cold tablet described in claim l suppresses the application in mice teratocarcinoma cell F9 cell proliferation medicine in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310652780.3A CN103751424A (en) | 2013-12-06 | 2013-12-06 | Preparation method of cold tablet containing Artemisia carvifolia and holly root, and application of cold tablet in teratoma cell F9 cell proliferation inhibition medicines. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310652780.3A CN103751424A (en) | 2013-12-06 | 2013-12-06 | Preparation method of cold tablet containing Artemisia carvifolia and holly root, and application of cold tablet in teratoma cell F9 cell proliferation inhibition medicines. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103751424A true CN103751424A (en) | 2014-04-30 |
Family
ID=50518851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310652780.3A Pending CN103751424A (en) | 2013-12-06 | 2013-12-06 | Preparation method of cold tablet containing Artemisia carvifolia and holly root, and application of cold tablet in teratoma cell F9 cell proliferation inhibition medicines. |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103751424A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104288655A (en) * | 2014-10-16 | 2015-01-21 | 济南新起点医药科技有限公司 | Preparation method of fomes officinalis cough and asthma treating tablets and application of fomes officinalis cough and asthma treating tablets in preparation of medicine for inhibiting cell proliferation of mouse teratoma cell F9 |
| CN104288657A (en) * | 2014-10-16 | 2015-01-21 | 济南新起点医药科技有限公司 | Preparation method of fomes officinalis cough and asthma treating tablets and application of fomes officinalis cough and asthma treating tablets in preparation of medicine for inhibiting cell proliferation of mouse teratoma cell P19 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102988723A (en) * | 2012-10-08 | 2013-03-27 | 李正梅 | Preparation method and application of yin tonifying and calming tablet |
-
2013
- 2013-12-06 CN CN201310652780.3A patent/CN103751424A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102988723A (en) * | 2012-10-08 | 2013-03-27 | 李正梅 | Preparation method and application of yin tonifying and calming tablet |
Non-Patent Citations (5)
| Title |
|---|
| 刘伟、侯丽: ""青蒿及其有效成分抗肿瘤机制研究进展"", 《北京中医药》, vol. 31, no. 7, 31 July 2012 (2012-07-31), pages 552 - 555 * |
| 国家药品监督管理局: ""青梅感冒颗粒"", 《国家药品标准（试行）颁布件》, 16 November 2002 (2002-11-16), pages 339 - 342 * |
| 梅全喜主编: "《广东地产药材研究》", 31 May 2011, 广东科技出版社, article ""岗梅"", pages: 347 * |
| 范文昌等编著: "《广东地产清热解毒药物大全》", 31 July 2011, 中医古籍出版社, article ""积雪草"", pages: 522 * |
| 邹节明主编: "《广西特色中草药资源选编》", 31 August 2011, 科学出版社, article ""五指柑"", pages: 831 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104288655A (en) * | 2014-10-16 | 2015-01-21 | 济南新起点医药科技有限公司 | Preparation method of fomes officinalis cough and asthma treating tablets and application of fomes officinalis cough and asthma treating tablets in preparation of medicine for inhibiting cell proliferation of mouse teratoma cell F9 |
| CN104288657A (en) * | 2014-10-16 | 2015-01-21 | 济南新起点医药科技有限公司 | Preparation method of fomes officinalis cough and asthma treating tablets and application of fomes officinalis cough and asthma treating tablets in preparation of medicine for inhibiting cell proliferation of mouse teratoma cell P19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103655843B (en) | A kind of Yikang complement sheet and its preparation method and application | |
| CN103800498B (en) | A kind of preparation method of Armeniaca mume Sieb. common cold tablet and the application in suppression row adenocarcinoma cell RM-1 cell proliferation thereof | |
| CN103768211B (en) | A kind of preparation method of Armeniaca mume Sieb. common cold tablet and the application in suppression lymphoma cell EL4 cell proliferation thereof | |
| CN103751424A (en) | Preparation method of cold tablet containing Artemisia carvifolia and holly root, and application of cold tablet in teratoma cell F9 cell proliferation inhibition medicines. | |
| CN103690647B (en) | A kind of preparation method of Yikang complement sheet and the application in suppression mouse leukemia cell L6565 cell proliferation thereof | |
| CN103768262A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting myeloma cell FO from cell proliferation | |
| CN103800499A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting melanoma cell B16 from cell proliferation | |
| CN103768266A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting mouse leukaemia cell L6565 from cell proliferation | |
| CN103893411A (en) | Preparation method and application of green plum cold tablets | |
| CN103768263A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting cerebral nerve oncocyte Neuro-2a from cell proliferation | |
| CN103768267A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting lung cancer cell H22 from cell proliferation | |
| CN103751350B (en) | A kind of preparation method of Armeniaca mume Sieb. common cold tablet and the application in suppression leukaemia L1210 cell proliferation thereof | |
| CN103768207B (en) | A kind of preparation method of Armeniaca mume Sieb. common cold tablet and the application in suppression hepatoma carcinoma cell Hepa1-6 cell proliferation thereof | |
| CN103735960A (en) | Application of boenninghausenia sessilicarpa cough-asthma tablet to prepare medicaments for inhibiting lung cancer cell LLC proliferation | |
| CN103768212B (en) | The preparation method of a kind of Armeniaca mume Sieb. common cold tablet and the application in suppressing stomach cancer cell MFC cell proliferation thereof | |
| CN103768264A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting teratoma cell P19 from cell proliferation | |
| CN103768265A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting lung cancer cell LLC from cell proliferation | |
| CN103800569A (en) | Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting lymphoma cell YAC-1 from cell proliferation | |
| CN103751425A (en) | Preparation method of Qingmei cold-treatment tablet and use of Qingmei cold-treatment tablet in drug for inhibiting breast tumor cell C127 proliferation | |
| CN103768210B (en) | A kind of preparation method of Armeniaca mume Sieb. common cold tablet and the application in suppression anus sarcoma cell S-180 cell proliferation thereof | |
| CN103751351B (en) | A kind of preparation method of Armeniaca mume Sieb. common cold tablet and the application in suppression leydig cell tumor of testis cell MLTC-1 cell proliferation thereof | |
| CN103768209B (en) | A kind of preparation method of Armeniaca mume Sieb. common cold tablet and the application in suppression myeloma cell P3X63AG8 cell proliferation thereof | |
| CN103800770A (en) | Application of boenninghausenia cough tablet in preparing medicine for inhibiting cell proliferation of breast tumor cell C127 | |
| CN103751423A (en) | Preparation method of cold tablet containing Artemisia carvifolia and holly root, and application of cold tablet in mastocytoma cell P815 cell proliferation inhibition medicines | |
| CN103655838B (en) | Preparation method of Yikangbuyuan tablet and application of Yikangbuyuan tablet in medicines for inhibiting mouse lymphomata cell L5178Y proliferation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140430 |
|
| RJ01 | Rejection of invention patent application after publication |